We develop a gene transfer strategy into hematopoietic cells to target specific anti-tumor proteins. A definite vector delivers the gene into the cells. We use a combination of transcriptional and mediated control gene expression to selectively direct the anti-tumor proteins to the tumor area. Based on our exclusive mechanism, the immune system cells are reactivated and armed with a potent drug.
Genenta has obtained regulatory approvals to initiate Phase I/II clinical trials in Multiple Myeloma patients with early relapse after front line therapy and newly diagnosed Glioblastoma Multiforme patients.
Luigi Naldini, Winner of the 2019 Jeantet-Collen Prize for Translational Medicine
Genenta Science is a company developing a new generation of gene therapies based on transcriptional and mirRNA-mediated control.LEARN MORE
Using gene vectors, microRNA targets sequences and transgenes for preventing or reducing expression of the transgenes.LEARN MORE
Genenta Science is leveraging its Temferon™ technology platform to treat cancers using a novel immuno-gene therapy approachLEARN MORE
March, 2015. Genenta Science banked an overall USD 11.0 million Series A round.LEARN MORE
LUIGI NALDINI is the Director of the San Raffaele Telethon Institute for Gene Therapy and Professor at the San Raffaele University and Milan, Italy. He has pioneered the development and applications of lentiviral vectors for gene therapy and contributed to advance targeted genome editing in cell and gene therapy. He is member of EMBO, past President of ESGCT, and received the Outstanding Achievement Award from ASGCT in 2014 and from ESGCT in 2015, the Beutler Prize from ASH in 2017 and the 2019 Jeantet-Collen Prize for Translational Medicine.